Back to Results

Bone Biologics Corp (BBLG)

Bone Biologics Corp is a healthcare company focused on bone regeneration in spinal fusion. The company develops medical device products built around NELL-1, including a lead NELL-1/DBM device designed to support bone growth in spinal applications. It is also working on NB1, a fusion device intended for lumbar spinal fusion, along with related uses in spine implants, non-union trauma cases, and osteoporosis. Bone Biologics says its products are aimed at spine surgeons and patients with bone defects or bone-related conditions affecting the spine. The company has a license agreement with UCLA Technology Development Group covering NELL-1 for spinal fusion, osteoporosis, and trauma-related applications. Bone Biologics was founded in 2004 and is based in Burlington, Massachusetts.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-BBLG
$0.45
38.8% Upside
Undervalued
$12.20 3,668.9% Upside
Not available
Bargain
Weak
0.0%
December 2, 2026
0.2x
1.097 M
-4.999 M
0.0%
100.0%
-26.6
90.4%
Valuation • Fair Value

Bone Biologics Corp (NASDAQ-BBLG) Fair Value by Valuation Model

Review the available estimates for Bone Biologics Corp (NASDAQ-BBLG), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.45

Estimated upside of 38.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.45

Comparable-company valuation reference.

Analyst Price Target

$12.20 3,668.9% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use the 4 available valuation references for Bone Biologics Corp (NASDAQ-BBLG) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Bone Biologics Corp (NASDAQ-BBLG)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Bone Biologics Corp (NASDAQ-BBLG) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Bone Biologics Corp (NASDAQ-BBLG)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

-26.6

Lower score that deserves closer risk review.

FCF / Net Income

90.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Bone Biologics Corp (NASDAQ-BBLG). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Bone Biologics Corp (NASDAQ-BBLG)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

December 2, 2026

Days to Earnings

26

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Bone Biologics Corp (NASDAQ-BBLG), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Bone Biologics Corp (NASDAQ-BBLG) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Bone Biologics Corp (NASDAQ-BBLG) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Bone Biologics Corp (NASDAQ-BBLG) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Bone Biologics Corp (NASDAQ-BBLG) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Bone Biologics Corp (NASDAQ-BBLG) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Bone Biologics Corp (NASDAQ-BBLG) Stock FAQ

Data-supported answers about Bone Biologics Corp (NASDAQ-BBLG), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.45
Estimated upside 38.8%
Valuation Rating
Undervalued
Estimated upside of 38.8%
Analyst Target
$12.20 3,668.9% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Bone Biologics Corp (NASDAQ-BBLG) is $0.45. This implies an estimated upside of 38.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 38.8% versus the current market price.

The available analyst price target for Bone Biologics Corp (NASDAQ-BBLG) is $12.20 3,668.9% Upside.

The current financial health read for Bone Biologics Corp (NASDAQ-BBLG) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Bone Biologics Corp (NASDAQ-BBLG) is December 2, 2026.

The latest available data indicates no current dividend yield for Bone Biologics Corp (NASDAQ-BBLG).

The current market capitalization listed for Bone Biologics Corp is 1.097 M.

The current enterprise value listed for Bone Biologics Corp is -4.999 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Bone Biologics Corp is NASDAQ-BBLG, and the stock is listed on NASDAQ.

Bone Biologics Corp (NASDAQ-BBLG) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Bone Biologics Corp is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Bone Biologics Corp is 100.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 509.5 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 249 B
GILD NASDAQ Gilead Sciences Inc Fair Value Overvalued Market Cap 207.9 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 137.5 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 96.399 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 90.518 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 57.239 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 52.434 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 44.031 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 38.077 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 36.058 B
GMAB NASDAQ Genmab AS Fair Value Fair Market Cap 32.603 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 26.451 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 24.093 B
INCY NASDAQ Incyte Corporation Fair Value Undervalued Market Cap 24.048 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 23.855 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 21.287 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Undervalued Market Cap 20.983 B
EXEL NASDAQ Exelixis Inc Fair Value Fair Market Cap 16.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 16.65 B